Ignite Creation Date:
2025-12-25 @ 1:12 AM
Ignite Modification Date:
2026-03-04 @ 8:46 PM
Study NCT ID:
NCT00646893
Status:
SUSPENDED
Last Update Posted:
2010-02-23
First Post:
2008-03-26
Is Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
Preimplantation Genetic Diagnosis for the Indication of Advanced Reproductive Age
Sponsor:
Organization:
Raw JSON
{'hasResults': False, 'derivedSection': {'miscInfoModule': {'versionHolder': '2025-12-24', 'removedCountries': ['Turkey (Türkiye)']}, 'conditionBrowseModule': {'meshes': [{'id': 'D007246', 'term': 'Infertility'}, {'id': 'D000782', 'term': 'Aneuploidy'}, {'id': 'D000022', 'term': 'Abortion, Spontaneous'}, {'id': 'D002869', 'term': 'Chromosome Aberrations'}], 'ancestors': [{'id': 'D000091662', 'term': 'Genital Diseases'}, {'id': 'D000091642', 'term': 'Urogenital Diseases'}, {'id': 'D010335', 'term': 'Pathologic Processes'}, {'id': 'D013568', 'term': 'Pathological Conditions, Signs and Symptoms'}, {'id': 'D011248', 'term': 'Pregnancy Complications'}, {'id': 'D005261', 'term': 'Female Urogenital Diseases and Pregnancy Complications'}]}}, 'protocolSection': {'designModule': {'phases': ['PHASE4'], 'studyType': 'INTERVENTIONAL', 'designInfo': {'allocation': 'RANDOMIZED', 'maskingInfo': {'masking': 'QUADRUPLE', 'whoMasked': ['PARTICIPANT', 'CARE_PROVIDER', 'INVESTIGATOR', 'OUTCOMES_ASSESSOR']}, 'primaryPurpose': 'SCREENING', 'interventionModel': 'PARALLEL'}, 'enrollmentInfo': {'type': 'ESTIMATED', 'count': 1200}}, 'statusModule': {'whyStopped': 'lack of appropriate funding', 'overallStatus': 'SUSPENDED', 'startDateStruct': {'date': '2008-06'}, 'expandedAccessInfo': {'hasExpandedAccess': False}, 'statusVerifiedDate': '2010-02', 'completionDateStruct': {'date': '2011-04', 'type': 'ESTIMATED'}, 'lastUpdateSubmitDate': '2010-02-21', 'studyFirstSubmitDate': '2008-03-26', 'studyFirstSubmitQcDate': '2008-03-28', 'lastUpdatePostDateStruct': {'date': '2010-02-23', 'type': 'ESTIMATED'}, 'studyFirstPostDateStruct': {'date': '2008-03-31', 'type': 'ESTIMATED'}, 'primaryCompletionDateStruct': {'date': '2011-01', 'type': 'ESTIMATED'}}, 'outcomesModule': {'primaryOutcomes': [{'measure': 'ongoing pregnancy rate (past 2nd trimester).', 'timeFrame': 'after 21 days, 20 weeks, and 7 month of treatment'}], 'secondaryOutcomes': [{'measure': 'spontaneous abortions', 'timeFrame': 'within 1st and 2nd trimester'}, {'measure': 'pregnancy', 'timeFrame': 'one month for presence of fetal sac'}, {'measure': 'implantation', 'timeFrame': 'first month, for presence of fetal sacs'}]}, 'oversightModule': {'oversightHasDmc': True}, 'conditionsModule': {'keywords': ['aneuploidy', 'miscarriage', 'pregnancy loss', 'PGD', 'PGS', 'Preimplantation Genetic Diagnosis', 'chromosome abnormalities', 'IVF', 'ART'], 'conditions': ['Infertility']}, 'referencesModule': {'references': [{'pmid': '17296179', 'type': 'BACKGROUND', 'citation': 'Colls P, Escudero T, Cekleniak N, Sadowy S, Cohen J, Munne S. Increased efficiency of preimplantation genetic diagnosis for infertility using "no result rescue". Fertil Steril. 2007 Jul;88(1):53-61. doi: 10.1016/j.fertnstert.2006.11.099. Epub 2007 Feb 12.'}]}, 'descriptionModule': {'briefSummary': 'The objective of this study is to demonstrate that Preimplantation Genetic diagnosis will significantly reduce spontaneous abortions and increase ongoing pregnancy rates in patients of advanced maternal age (37-42) undergoing IVF. We would like to test this hypothesis by a randomized trial performed with the most suitable conditions using very successful IVF laboratories capable to perform the embryo biopsy under strict controlled conditions after proper training and validation of the techniques.', 'detailedDescription': 'Indications: Patients of advanced reproductive age wishing to receive preimplantation genetic screening in ART.\n\nObjectives: To demonstrate that Preimplantation Genetic diagnosis (PGD) will significantly reduce spontaneous abortions and increase ongoing pregnancy rates in patients of advanced maternal age (37-42) undergoing IVF.\n\nTest Method: Preimplantation Genetic Screening through FISH Treatment: In Vitro Fertilization treatment. The resulting embryos of the test group will undergo embryo biopsy followed by PGD with FISH using a 10-probe test with "no result rescue".\n\nStudy Population: 978 infertile women undergoing ART Major Inclusions: Premenopausal infertile women wishing to conceive, aged 37 42 years, inclusive, regular menstrual cycles and screening early follicular phase FSH within normal limits.\n\nMajor Exclusions: Clinically significant systemic disease; any contraindication to pregnancy or carrying pregnancy to term; known ASRM Grade III or IV endometriosis; clinically significant abnormal findings on a transvaginal ultrasound within 6 weeks prior to the beginning of OCP treatment; extrauterine pregnancy within 3 months prior to the beginning of OCP treatment; poor response in a previous ART cycle (≤ 3 oocytes retrieved); ≥ 3 prior, initiated, consecutive ART cycles without a clinical pregnancy; prior severe OHSS; TESA and TESE patients; patients carriers of chromosomal or genetic diseases.\n\nRandomization: Eligible patients will be randomized in a 1:1 ratio to either:\n\nGroup A: Hatching "or" Group B: Hatching + PGS Study Procedures The study will be conducted on an outpatient basis. All pre-study screening assessments will be performed prior to treatment start.\n\nPost-treatment Oocyte retrieval and embryology procedures will be Procedures performed according to the usual practice of the study center. Test Method Hatching, embryo biopsy, fixation and Fluorescence in-situ Hybridization (FISH) will be performed strictly in line with the methodology included in this protocol and only carried out by technicians certified by Reprogenetics.\n\nPrimary Endpoint: ongoing pregnancy rate (past 2nd trimester). Secondary Endpoints: implantation rate, pregnancy rate, miscarriage rate and live birth.'}, 'eligibilityModule': {'sex': 'FEMALE', 'stdAges': ['ADULT'], 'maximumAge': '42 Years', 'minimumAge': '37 Years', 'healthyVolunteers': False, 'eligibilityCriteria': 'Inclusion Criteria:\n\n* Premenopausal infertile women wishing to conceive\n* Aged 37 42 years, inclusive,\n* Regular menstrual cycles (generally 25 35 days in length) and screening early follicular phase FSH within normal limits.\n\nExclusion Criteria:\n\n* Clinically significant systemic disease;\n* Any contraindication to pregnancy or carrying pregnancy to term;\n* Known ASRM Grade III or IV endometriosis;\n* Clinically significant abnormal findings on a transvaginal ultrasound within 6 weeks prior to the beginning of OCP treatment;\n* Extrauterine pregnancy within 3 months prior to the beginning of OCP treatment;\n* ≥ 3 prior, initiated, consecutive ART cycles without a clinical pregnancy;\n* Prior severe OHSS;\n* TESA and TESE patients;\n* Patients carriers of chromosomal or genetic diseases.\n* Egg donation cycles.\n* Frozen Cycles.'}, 'identificationModule': {'nctId': 'NCT00646893', 'briefTitle': 'Preimplantation Genetic Diagnosis for the Indication of Advanced Reproductive Age', 'organization': {'class': 'INDUSTRY', 'fullName': 'Reprogenetics'}, 'officialTitle': 'Comparison of Embryo Transfer With and Without PGS for the Indication of Advanced Reproductive Age (37-42) in Patients Undergoing ART', 'orgStudyIdInfo': {'id': 'Reprogenetics-01'}}, 'armsInterventionsModule': {'armGroups': [{'type': 'NO_INTERVENTION', 'label': '1', 'description': 'Control: assisted hatching, without Preimplantation Genetic Diagnosis'}, {'type': 'EXPERIMENTAL', 'label': '2', 'description': 'Test: embryo biopsy with Preimplantation Genetic Diagnosis', 'interventionNames': ['Procedure: Preimplantation Genetic Diagnosis (PGD)']}], 'interventions': [{'name': 'Preimplantation Genetic Diagnosis (PGD)', 'type': 'PROCEDURE', 'otherNames': ['PGS', 'Preimplantation Genetic Screening'], 'description': 'one-cell embryo biopsy on day 3 of development. The cell will be analyzed by FISH using probes for X,Y,13,15,16,17,18,21,22 chromosomes. Cells with dubious results will be reanalyzed by "no result rescue" (Colls et al. 2007)', 'armGroupLabels': ['2']}]}, 'contactsLocationsModule': {'locations': [{'zip': '90210', 'city': 'Beverly Hills', 'state': 'California', 'country': 'United States', 'facility': 'ART Reproductive Center,', 'geoPoint': {'lat': 34.07362, 'lon': -118.40036}}, {'zip': '60035', 'city': 'Highland Park', 'state': 'Illinois', 'country': 'United States', 'facility': 'Fertility Centers of Illinois', 'geoPoint': {'lat': 42.18169, 'lon': -87.80034}}, {'zip': '07039', 'city': 'Livingston', 'state': 'New Jersey', 'country': 'United States', 'facility': 'Institute for Reproductive Medicine and Science at Saint Barnabas Medical Center', 'geoPoint': {'lat': 40.79593, 'lon': -74.31487}}, {'zip': '07039', 'city': 'Livingston', 'state': 'New Jersey', 'country': 'United States', 'facility': 'Reprogenetics', 'geoPoint': {'lat': 40.79593, 'lon': -74.31487}}, {'city': 'Barcelona', 'state': 'Barcelona', 'country': 'Spain', 'facility': 'IVI Barcelona', 'geoPoint': {'lat': 41.38879, 'lon': 2.15899}}], 'overallOfficials': [{'name': 'Santiago Munne, PhD', 'role': 'PRINCIPAL_INVESTIGATOR', 'affiliation': 'Reprogenetics'}]}, 'sponsorCollaboratorsModule': {'leadSponsor': {'name': 'Reprogenetics', 'class': 'INDUSTRY'}, 'responsibleParty': {'oldNameTitle': 'Santiago Munne', 'oldOrganization': 'Reprogenetics'}}}}